Literature DB >> 11924806

Anesthesia protocol for hyperpnea-induced airway obstruction in the guinea pig.

J Rhodes1, T D Mickleborough, J Owiny, A Tucker.   

Abstract

Guinea pigs (GP; Cavia porcellus) are used extensively as an experimental animal model in a wide range of disciplines including respiratory physiology. Guinea pigs are difficult to anesthetize, and many investigators use paralytic agents to eliminate spontaneous respiratory movements; however, strict federal regulations and institutional policies governing use of paralytic agents are few. We report an anesthesia protocol, using the injectable anesthetic agents sodium pentobarbital (SP) and xylazine (XYL) for the GP that induces consistent anesthesia while eliminating use of paralytic agents. Sixty percent of the calculated SP dose (45 mg/kg of body weight) was given for anesthesia induction, followed by 50% of the calculated XYL dose (7 mg/kg) 15 min later. Depth of anesthesia was monitored by response to toe pinch, ECG, and spontaneous respiratory movements. The animals were given additional boosts of SP (5 to 15% of the original dose, i.p. or i.v.) if a change in anesthesia depth was noted. Thirty-one animals completed the hyperpnea-induced bronchoconstriction (HIB) study with no fatalities. Using this protocol, we collected consistent, repeatable, and reliable data without use of propranolol or skeletal muscle paralytics. We believe that this protocol is not restricted to the GP and could be adapted for use in other terminal experiments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11924806

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  1 in total

1.  Efficacy and safety of five injectable anesthetic regimens for chronic blood collection from the anterior vena cava of Guinea pigs.

Authors:  Vi Dang; Saran Bao; Alida Ault; Catherine Murray; Joy McFarlane-Mills; Carmelo Chiedi; Marlon Dillon; John-Paul Todd; Louis Detolla; Srinivas Rao
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-11       Impact factor: 1.232

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.